Margarida Maia, PhD,  science writer—

Genetic testing may allow for the timely use of anti-complement therapy for atypical hemolytic uremic syndrome (aHUS), even if an infection with Shiga toxin-producing Escherichia coli (STEC), a trigger of the typical form of the disease, is present and initially upstages the correct diagnosis of aHUS. In a…

The use of Soliris (eculizumab) is changing the natural course of atypical hemolytic uremic syndrome (aHUS) in Latin America as it has in other regions, helping many patients achieve better outcomes, according to a review study. While aHUS arises from the same genetic causes and manifests in a…

Adults with atypical hemolytic uremic syndrome (aHUS) who switched from Soliris (eculizumab) to long-acting Ultomiris (ravulizumab) in a real-world setting experienced no new side effects or worsening of symptoms for up to a year, a study has found. Switching to Ultomiris may be more convenient for patients…

The U.S. Food and Drug Administration (FDA) has approved Bkemv (eculizumab-aeeb), the first interchangeable biosimilar to Soliris (eculizumab), to treat people with atypical hemolytic uremic syndrome (aHUS). A biosimilar is a medication highly similar to a reference biologic — a medication made from natural, living sources like bacteria —…

In a young girl, thrombotic microangiopathy — a group of disorders, including atypical hemolytic uremic syndrome (aHUS), that are marked by organ damage caused by the formation of blood clots inside small blood vessels — occurred secondary to a sudden spike in blood pressure. Because the opposite is more…

A team of five experts from across Spain got together to reach a consensus on a set of recommendations for how to best manage atypical hemolytic uremic syndrome (aHUS) in adults. The consensus offers guidance for doctors with less experience in managing the disease. It covers the entire patient…

A rare mutation in the CFHR5 gene may have led to the excessive activation of the immune complement system, triggering atypical hemolytic uremic syndrome (aHUS) in a 5-year-old girl, a case study reports. The mutation in CFHR5 (which stands for complement factor H-related protein 5) was found to reduce…

Alexion, AstraZeneca Rare Disease signed off on a letter of intent in Canada that brings Ultomiris (ravulizumab) — approved in the country for certain people with atypical hemolytic uremic syndrome (aHUS) — a step closer to becoming available under public drug plans. The letter, to the pan-Canadian Pharmaceutical…

Getting vaccinated against COVID-19 may protect people with atypical hemolytic uremic syndrome (aHUS) from the infection’s severe complications, without raising major safety issues, a small study finds. Receiving a double booster shot may be important to provide full protection, especially for transplant patients. “Our findings support the use of COVID-19…

Plasma exchange combined with rituximab, an immunosuppressant, might prevent atypical hemolytic uremic syndrome (aHUS) from coming back after a kidney transplant, according to a small study from India. The study, “Kidney Transplant Outcomes in Patients with Atypical Hemolytic Uremic Syndrome,” was published in Transplantation Proceedings. aHUS is…